Skip to main content


The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

15 year-old Amelia Cooper was one of over 150 children who visited Washington, DC as delegates for JDRF Children's Congress on July 13-15. She and other children and...
By Christie Auyeung Last summer, the Diabetes Research Connection (DRC) officially launched a novel crowdfunding platform that directly connects donors with early-career...
Moving the field closer to finding a cure in humans through an innovative tissue donation program – find out how you can support this work!
TZD drug pioglitazone becomes second-ever diabetes drug to reduce heart disease and first to reduce strokes. Who might this benefit most?
Strong results from the IMPACT study in low-A1c users.
Type 1 diabetes has been prevented and cured in more than 500 ways in mice, but never in humans. nPOD researchers are trying to change that, one donated organ at a time.
Highlights from the first study of a commercial automated insulin delivery device. Plus, Medtronic’s latest software updates!
Views on FDA regulation, pipeline updates, and first vs. next-generation systems.
Significant Improvement in A1c and time-in-range when adding CGM.
How many people have type 1? What are the barriers to using new therapies? What outcomes matter beyond A1c?
AADE’s Dr. Susan Guzman and diaTribe ’s Adam Brown discuss how common stigma is, why it matters, and tips to overcome it
New study shows that beta cell fragility may contribute to the risk of both type 1 and type 2 diabetes.
less risk of diabetes complications, lower A1c, improved weight loss and hypoglycemia; led by Novo Nordisk’s Victoza and semaglutide
How close is the UN to achieving its goal of “halting the rise in diabetes and obesity” by 2025?
No fingersticks needed? Plus, a look at the “thinnest CGM ever” from Dexcom and Verily
Making major improvements over current standard of care – how does this new treatment work? The FDA recently approved a new indication for a product that has been used...
JDRF and Helmsley Charitable Trust workshop highlights future goals and expectations for glucose-responsive insulin.
People with type 2 diabetes should contact their physicians if they notice new pain, sores, or infections on their legs or feet.
LEADER results announced at #2016ADA – compared to placebo, Victoza reduces risk of cardiovascular death by 22%, plus a 22% reduction in kidney disease. More results...
The artificial pancreas is here for those willing to build their own; what can manufacturers learn from OpenAPS?